Sachin Wani
Concepts (638)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Barrett Esophagus | 112 | 2026 | 169 | 34.400 |
Why?
| | Esophageal Neoplasms | 87 | 2026 | 348 | 24.160 |
Why?
| | Adenocarcinoma | 72 | 2026 | 925 | 13.200 |
Why?
| | Esophagoscopy | 58 | 2026 | 223 | 11.510 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 45 | 2026 | 223 | 10.160 |
Why?
| | Gastroenterology | 31 | 2026 | 191 | 9.030 |
Why?
| | Endosonography | 38 | 2024 | 160 | 8.810 |
Why?
| | Precancerous Conditions | 30 | 2025 | 166 | 8.160 |
Why?
| | Endoscopy, Gastrointestinal | 43 | 2026 | 237 | 7.800 |
Why?
| | Endoscopy, Digestive System | 25 | 2023 | 142 | 6.700 |
Why?
| | Quality Indicators, Health Care | 19 | 2024 | 336 | 6.020 |
Why?
| | Colonoscopy | 33 | 2025 | 263 | 5.990 |
Why?
| | Colonic Polyps | 22 | 2025 | 87 | 5.550 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 20 | 2024 | 61 | 4.920 |
Why?
| | Gastroesophageal Reflux | 19 | 2023 | 237 | 4.370 |
Why?
| | Clinical Competence | 29 | 2026 | 1243 | 4.300 |
Why?
| | Esophagus | 22 | 2025 | 262 | 3.960 |
Why?
| | Pancreatic Neoplasms | 23 | 2024 | 928 | 3.120 |
Why?
| | Learning Curve | 13 | 2024 | 71 | 3.070 |
Why?
| | Endoscopic Mucosal Resection | 11 | 2024 | 38 | 2.760 |
Why?
| | Adenoma | 17 | 2023 | 218 | 2.700 |
Why?
| | Pancreatitis | 16 | 2025 | 146 | 2.700 |
Why?
| | Population Surveillance | 12 | 2024 | 484 | 2.660 |
Why?
| | Gastrointestinal Diseases | 9 | 2022 | 221 | 2.580 |
Why?
| | Humans | 309 | 2026 | 145475 | 2.500 |
Why?
| | Endoscopy | 15 | 2021 | 317 | 2.320 |
Why?
| | Biopsy | 24 | 2025 | 1082 | 2.210 |
Why?
| | Early Detection of Cancer | 15 | 2025 | 485 | 1.960 |
Why?
| | Cholangitis | 6 | 2024 | 22 | 1.870 |
Why?
| | Watchful Waiting | 9 | 2026 | 90 | 1.800 |
Why?
| | Stents | 17 | 2025 | 564 | 1.790 |
Why?
| | Pancreatic Cyst | 4 | 2020 | 50 | 1.780 |
Why?
| | Colorectal Neoplasms | 14 | 2023 | 866 | 1.770 |
Why?
| | Fellowships and Scholarships | 6 | 2026 | 354 | 1.630 |
Why?
| | Prospective Studies | 47 | 2026 | 8057 | 1.610 |
Why?
| | Guideline Adherence | 5 | 2021 | 586 | 1.580 |
Why?
| | Narrow Band Imaging | 8 | 2022 | 14 | 1.540 |
Why?
| | Catheter Ablation | 8 | 2022 | 355 | 1.540 |
Why?
| | Societies, Medical | 10 | 2026 | 899 | 1.540 |
Why?
| | Bile Duct Neoplasms | 5 | 2023 | 131 | 1.530 |
Why?
| | Disease Progression | 22 | 2025 | 2864 | 1.520 |
Why?
| | Education, Medical, Graduate | 9 | 2026 | 562 | 1.440 |
Why?
| | Sphincterotomy, Endoscopic | 10 | 2024 | 29 | 1.430 |
Why?
| | Pancreatic Diseases | 10 | 2020 | 66 | 1.340 |
Why?
| | Aged | 84 | 2026 | 26153 | 1.340 |
Why?
| | Middle Aged | 102 | 2026 | 36215 | 1.330 |
Why?
| | Hyperplasia | 8 | 2024 | 177 | 1.300 |
Why?
| | Choledocholithiasis | 4 | 2026 | 20 | 1.210 |
Why?
| | Neoplasm Recurrence, Local | 7 | 2026 | 1149 | 1.200 |
Why?
| | Fiducial Markers | 2 | 2019 | 9 | 1.190 |
Why?
| | Male | 118 | 2026 | 72843 | 1.150 |
Why?
| | Pancreas | 10 | 2024 | 341 | 1.150 |
Why?
| | Gastrointestinal Neoplasms | 3 | 2024 | 73 | 1.130 |
Why?
| | Female | 115 | 2026 | 78845 | 1.080 |
Why?
| | Registries | 9 | 2025 | 2406 | 1.070 |
Why?
| | United States | 41 | 2026 | 16098 | 1.060 |
Why?
| | Needles | 5 | 2024 | 63 | 1.000 |
Why?
| | Incidence | 21 | 2026 | 2923 | 1.000 |
Why?
| | Ampulla of Vater | 4 | 2023 | 40 | 1.000 |
Why?
| | Ablation Techniques | 4 | 2024 | 36 | 0.970 |
Why?
| | Benchmarking | 4 | 2022 | 191 | 0.970 |
Why?
| | Esophagectomy | 7 | 2023 | 135 | 0.950 |
Why?
| | Esophagitis, Peptic | 3 | 2023 | 16 | 0.950 |
Why?
| | Catheterization | 9 | 2024 | 183 | 0.940 |
Why?
| | Biopsy, Fine-Needle | 4 | 2017 | 68 | 0.930 |
Why?
| | Rectum | 2 | 2019 | 182 | 0.930 |
Why?
| | Esophageal Achalasia | 3 | 2021 | 29 | 0.930 |
Why?
| | Intestinal Polyps | 2 | 2016 | 14 | 0.920 |
Why?
| | Practice Guidelines as Topic | 12 | 2025 | 1581 | 0.900 |
Why?
| | Digestive System Diseases | 3 | 2015 | 28 | 0.890 |
Why?
| | Observer Variation | 14 | 2025 | 357 | 0.890 |
Why?
| | Cholestasis | 4 | 2023 | 214 | 0.870 |
Why?
| | Gastrointestinal Hemorrhage | 5 | 2024 | 138 | 0.870 |
Why?
| | Aptitude | 2 | 2015 | 30 | 0.870 |
Why?
| | Biliary Tract Diseases | 5 | 2020 | 33 | 0.860 |
Why?
| | Laryngopharyngeal Reflux | 2 | 2021 | 14 | 0.850 |
Why?
| | Pepsin A | 2 | 2021 | 18 | 0.850 |
Why?
| | Incidental Findings | 1 | 2025 | 81 | 0.840 |
Why?
| | Self-Assessment | 1 | 2025 | 74 | 0.840 |
Why?
| | Self Expandable Metallic Stents | 2 | 2021 | 17 | 0.830 |
Why?
| | Practice Patterns, Physicians' | 6 | 2021 | 1371 | 0.830 |
Why?
| | Pancreatic Ducts | 7 | 2024 | 82 | 0.830 |
Why?
| | Margins of Excision | 1 | 2024 | 50 | 0.820 |
Why?
| | Lymph Nodes | 4 | 2015 | 503 | 0.800 |
Why?
| | Treatment Outcome | 31 | 2026 | 11772 | 0.800 |
Why?
| | Taurine | 1 | 2023 | 41 | 0.790 |
Why?
| | Colonic Pseudo-Obstruction | 2 | 2020 | 4 | 0.780 |
Why?
| | Neoplasm Staging | 8 | 2024 | 1471 | 0.770 |
Why?
| | Intestinal Volvulus | 2 | 2020 | 23 | 0.750 |
Why?
| | Drainage | 8 | 2024 | 185 | 0.730 |
Why?
| | Time-to-Treatment | 1 | 2024 | 251 | 0.730 |
Why?
| | Disease Management | 3 | 2021 | 653 | 0.720 |
Why?
| | Stomach Diseases | 2 | 2014 | 20 | 0.720 |
Why?
| | Rectal Diseases | 2 | 2019 | 24 | 0.700 |
Why?
| | Endoscopes | 2 | 2021 | 17 | 0.690 |
Why?
| | Postoperative Complications | 6 | 2025 | 2970 | 0.690 |
Why?
| | Teaching Rounds | 1 | 2022 | 74 | 0.680 |
Why?
| | Deglutition Disorders | 2 | 2021 | 154 | 0.670 |
Why?
| | Esophageal Sphincter, Lower | 2 | 2021 | 14 | 0.660 |
Why?
| | Equipment Reuse | 1 | 2021 | 18 | 0.660 |
Why?
| | Esophageal Diseases | 2 | 2014 | 30 | 0.660 |
Why?
| | Dilatation | 3 | 2019 | 71 | 0.650 |
Why?
| | Argon Plasma Coagulation | 1 | 2020 | 6 | 0.650 |
Why?
| | Hemostasis, Endoscopic | 1 | 2020 | 2 | 0.640 |
Why?
| | Cohort Studies | 13 | 2026 | 6013 | 0.640 |
Why?
| | Sensitivity and Specificity | 19 | 2023 | 1997 | 0.640 |
Why?
| | Retrospective Studies | 37 | 2026 | 17291 | 0.630 |
Why?
| | Biomarkers, Tumor | 2 | 2025 | 1321 | 0.630 |
Why?
| | Competency-Based Education | 2 | 2024 | 81 | 0.630 |
Why?
| | Referral and Consultation | 4 | 2024 | 867 | 0.630 |
Why?
| | Gastrointestinal Stromal Tumors | 2 | 2017 | 41 | 0.630 |
Why?
| | Delphi Technique | 6 | 2024 | 332 | 0.620 |
Why?
| | Pancreatectomy | 3 | 2021 | 289 | 0.620 |
Why?
| | Heller Myotomy | 1 | 2019 | 2 | 0.620 |
Why?
| | Time Factors | 15 | 2026 | 7123 | 0.620 |
Why?
| | Acetylcholine Release Inhibitors | 1 | 2019 | 5 | 0.620 |
Why?
| | Sigmoid Diseases | 1 | 2019 | 14 | 0.610 |
Why?
| | Esophageal Motility Disorders | 1 | 2020 | 30 | 0.610 |
Why?
| | Adult | 50 | 2026 | 40777 | 0.600 |
Why?
| | SEER Program | 4 | 2020 | 229 | 0.600 |
Why?
| | Bile Ducts | 3 | 2014 | 68 | 0.600 |
Why?
| | Cholinesterase Inhibitors | 1 | 2019 | 47 | 0.600 |
Why?
| | Proctoscopy | 1 | 2019 | 5 | 0.600 |
Why?
| | Predictive Value of Tests | 18 | 2025 | 2121 | 0.600 |
Why?
| | Carcinoma | 3 | 2021 | 225 | 0.590 |
Why?
| | Conflict of Interest | 1 | 2020 | 54 | 0.590 |
Why?
| | Medical Overuse | 1 | 2019 | 30 | 0.590 |
Why?
| | Recurrence | 5 | 2026 | 1138 | 0.580 |
Why?
| | Botulinum Toxins | 1 | 2019 | 48 | 0.580 |
Why?
| | Conservative Treatment | 1 | 2019 | 45 | 0.580 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2019 | 39 | 0.580 |
Why?
| | Risk Factors | 23 | 2025 | 10885 | 0.580 |
Why?
| | Quality of Health Care | 2 | 2021 | 692 | 0.580 |
Why?
| | Decompression, Surgical | 1 | 2019 | 116 | 0.570 |
Why?
| | Racism | 1 | 2021 | 146 | 0.570 |
Why?
| | Aged, 80 and over | 24 | 2026 | 8333 | 0.570 |
Why?
| | Colonic Neoplasms | 7 | 2022 | 257 | 0.560 |
Why?
| | Acute Disease | 8 | 2024 | 1036 | 0.550 |
Why?
| | Family Health | 1 | 2019 | 191 | 0.550 |
Why?
| | Consensus | 5 | 2025 | 477 | 0.540 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 170 | 0.540 |
Why?
| | Stomach Neoplasms | 4 | 2024 | 128 | 0.540 |
Why?
| | Intestinal Perforation | 2 | 2016 | 46 | 0.540 |
Why?
| | Radiation Injuries | 1 | 2019 | 149 | 0.530 |
Why?
| | Prosthesis Implantation | 1 | 2019 | 154 | 0.530 |
Why?
| | Cytological Techniques | 1 | 2017 | 27 | 0.520 |
Why?
| | Risk Assessment | 11 | 2025 | 3747 | 0.500 |
Why?
| | Evidence-Based Medicine | 7 | 2025 | 740 | 0.500 |
Why?
| | Quality Assurance, Health Care | 1 | 2019 | 342 | 0.490 |
Why?
| | Cathartics | 1 | 2016 | 15 | 0.490 |
Why?
| | Metaplasia | 10 | 2023 | 57 | 0.490 |
Why?
| | Carcinoma, Squamous Cell | 5 | 2026 | 641 | 0.490 |
Why?
| | Diagnostic Tests, Routine | 1 | 2017 | 107 | 0.490 |
Why?
| | Carcinoembryonic Antigen | 2 | 2018 | 40 | 0.480 |
Why?
| | Documentation | 2 | 2023 | 199 | 0.480 |
Why?
| | Osteitis Deformans | 3 | 2023 | 9 | 0.470 |
Why?
| | Diarrhea | 3 | 2019 | 193 | 0.470 |
Why?
| | Hospitals | 1 | 2021 | 732 | 0.470 |
Why?
| | Indomethacin | 3 | 2025 | 76 | 0.470 |
Why?
| | Specimen Handling | 1 | 2017 | 182 | 0.470 |
Why?
| | Natural Orifice Endoscopic Surgery | 4 | 2026 | 35 | 0.460 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 27 | 0.460 |
Why?
| | Adenomatous Polyps | 1 | 2015 | 9 | 0.460 |
Why?
| | Liver Neoplasms | 4 | 2024 | 776 | 0.450 |
Why?
| | Cystadenoma, Mucinous | 1 | 2015 | 11 | 0.450 |
Why?
| | Cystadenocarcinoma, Mucinous | 1 | 2015 | 12 | 0.450 |
Why?
| | Pathology, Clinical | 1 | 2015 | 29 | 0.450 |
Why?
| | Hypnotics and Sedatives | 2 | 2020 | 222 | 0.450 |
Why?
| | Jaundice, Obstructive | 1 | 2014 | 3 | 0.440 |
Why?
| | Quality Improvement | 2 | 2021 | 1295 | 0.440 |
Why?
| | Duodenal Diseases | 1 | 2014 | 8 | 0.440 |
Why?
| | Aftercare | 4 | 2023 | 222 | 0.430 |
Why?
| | Pancreaticoduodenectomy | 1 | 2016 | 137 | 0.430 |
Why?
| | Ultrasonography, Interventional | 2 | 2019 | 165 | 0.430 |
Why?
| | Foreign-Body Migration | 1 | 2014 | 33 | 0.420 |
Why?
| | Mucous Membrane | 9 | 2015 | 128 | 0.420 |
Why?
| | Colectomy | 1 | 2015 | 106 | 0.410 |
Why?
| | Duodenum | 1 | 2014 | 77 | 0.410 |
Why?
| | Neoplasms | 3 | 2020 | 2906 | 0.410 |
Why?
| | Delivery of Health Care | 1 | 2021 | 946 | 0.410 |
Why?
| | Advisory Committees | 5 | 2014 | 229 | 0.410 |
Why?
| | Cholecystectomy | 3 | 2019 | 61 | 0.400 |
Why?
| | Curriculum | 2 | 2024 | 1070 | 0.400 |
Why?
| | Logistic Models | 9 | 2025 | 2134 | 0.390 |
Why?
| | Multimodal Imaging | 1 | 2014 | 129 | 0.390 |
Why?
| | Hemorrhage | 4 | 2020 | 822 | 0.390 |
Why?
| | Intestinal Mucosa | 4 | 2015 | 675 | 0.390 |
Why?
| | Precision Medicine | 1 | 2017 | 459 | 0.380 |
Why?
| | Polyps | 1 | 2013 | 14 | 0.380 |
Why?
| | Internship and Residency | 3 | 2021 | 1267 | 0.380 |
Why?
| | Peutz-Jeghers Syndrome | 1 | 2012 | 10 | 0.380 |
Why?
| | Tomography, X-Ray Computed | 6 | 2020 | 2769 | 0.380 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2013 | 63 | 0.380 |
Why?
| | Education, Medical, Continuing | 3 | 2022 | 133 | 0.380 |
Why?
| | Positron-Emission Tomography | 1 | 2014 | 343 | 0.370 |
Why?
| | Enteral Nutrition | 3 | 2021 | 217 | 0.370 |
Why?
| | Reproducibility of Results | 16 | 2023 | 3413 | 0.370 |
Why?
| | Educational Measurement | 4 | 2025 | 326 | 0.360 |
Why?
| | Gastroenterologists | 2 | 2022 | 21 | 0.360 |
Why?
| | Cholecystitis | 3 | 2024 | 24 | 0.360 |
Why?
| | Health Care Costs | 1 | 2015 | 425 | 0.360 |
Why?
| | Mass Screening | 6 | 2025 | 1360 | 0.360 |
Why?
| | Multivariate Analysis | 7 | 2021 | 1547 | 0.360 |
Why?
| | Pancreatitis, Chronic | 3 | 2024 | 64 | 0.350 |
Why?
| | Pandemics | 6 | 2023 | 1707 | 0.350 |
Why?
| | Cholangiocarcinoma | 1 | 2013 | 108 | 0.350 |
Why?
| | Manometry | 3 | 2021 | 98 | 0.340 |
Why?
| | Follow-Up Studies | 11 | 2026 | 5423 | 0.340 |
Why?
| | Laparoscopy | 1 | 2015 | 481 | 0.330 |
Why?
| | Neuroendocrine Tumors | 3 | 2018 | 119 | 0.330 |
Why?
| | Propofol | 1 | 2011 | 85 | 0.330 |
Why?
| | Myotomy | 2 | 2021 | 15 | 0.330 |
Why?
| | Sex Factors | 5 | 2021 | 2105 | 0.330 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 389 | 0.330 |
Why?
| | Coronavirus Infections | 3 | 2020 | 383 | 0.320 |
Why?
| | Hypotension | 1 | 2011 | 127 | 0.320 |
Why?
| | Video Recording | 7 | 2019 | 217 | 0.320 |
Why?
| | Pathology, Surgical | 1 | 2010 | 6 | 0.320 |
Why?
| | Survival Rate | 4 | 2026 | 2090 | 0.320 |
Why?
| | Duodenal Neoplasms | 2 | 2023 | 26 | 0.310 |
Why?
| | Proportional Hazards Models | 3 | 2026 | 1327 | 0.310 |
Why?
| | Diagnostic Techniques, Digestive System | 2 | 2019 | 12 | 0.300 |
Why?
| | Education, Medical | 1 | 2013 | 275 | 0.300 |
Why?
| | Irritable Bowel Syndrome | 2 | 2019 | 29 | 0.290 |
Why?
| | Wandering Spleen | 1 | 2008 | 2 | 0.290 |
Why?
| | Odds Ratio | 4 | 2018 | 1082 | 0.290 |
Why?
| | Hernia, Hiatal | 4 | 2021 | 39 | 0.290 |
Why?
| | Informed Consent | 3 | 2022 | 198 | 0.290 |
Why?
| | Finland | 2 | 2026 | 78 | 0.280 |
Why?
| | Histocytochemistry | 4 | 2013 | 78 | 0.280 |
Why?
| | Computer-Assisted Instruction | 4 | 2024 | 70 | 0.280 |
Why?
| | Sweden | 2 | 2026 | 115 | 0.280 |
Why?
| | Image Enhancement | 6 | 2018 | 200 | 0.270 |
Why?
| | Surgeons | 2 | 2022 | 340 | 0.260 |
Why?
| | Microscopy, Confocal | 5 | 2020 | 319 | 0.260 |
Why?
| | Tertiary Care Centers | 4 | 2016 | 195 | 0.260 |
Why?
| | Decision Trees | 2 | 2019 | 78 | 0.260 |
Why?
| | Proton Pump Inhibitors | 3 | 2022 | 109 | 0.260 |
Why?
| | Constriction, Pathologic | 6 | 2023 | 249 | 0.260 |
Why?
| | Obesity | 5 | 2025 | 3116 | 0.260 |
Why?
| | Inflammatory Bowel Diseases | 2 | 2026 | 364 | 0.250 |
Why?
| | Liver Transplantation | 1 | 2014 | 826 | 0.250 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2025 | 345 | 0.250 |
Why?
| | Prognosis | 4 | 2025 | 4316 | 0.250 |
Why?
| | Malignant Catarrh | 1 | 2006 | 1 | 0.250 |
Why?
| | Goats | 1 | 2006 | 18 | 0.250 |
Why?
| | Sphincter of Oddi | 3 | 2024 | 5 | 0.250 |
Why?
| | Herpesviridae | 1 | 2006 | 21 | 0.250 |
Why?
| | Osteoclasts | 4 | 2023 | 54 | 0.250 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2024 | 372 | 0.250 |
Why?
| | Fluid Therapy | 2 | 2018 | 155 | 0.240 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 2 | 2019 | 24 | 0.240 |
Why?
| | Age Factors | 5 | 2020 | 3342 | 0.240 |
Why?
| | Picolinic Acids | 1 | 2006 | 8 | 0.240 |
Why?
| | Pyloromyotomy | 1 | 2026 | 3 | 0.240 |
Why?
| | Kidney Tubular Necrosis, Acute | 1 | 2006 | 26 | 0.240 |
Why?
| | Carrier State | 1 | 2006 | 78 | 0.230 |
Why?
| | Cause of Death | 2 | 2026 | 470 | 0.230 |
Why?
| | Genetic Predisposition to Disease | 4 | 2022 | 2378 | 0.230 |
Why?
| | Prevalence | 7 | 2023 | 2865 | 0.230 |
Why?
| | Lithotripsy | 3 | 2024 | 49 | 0.230 |
Why?
| | Pancreatic Pseudocyst | 3 | 2024 | 18 | 0.220 |
Why?
| | Thinness | 1 | 2025 | 100 | 0.220 |
Why?
| | Sphincter of Oddi Dysfunction | 1 | 2024 | 1 | 0.220 |
Why?
| | Singapore | 1 | 2025 | 27 | 0.220 |
Why?
| | Cattle Diseases | 1 | 2005 | 21 | 0.220 |
Why?
| | Diagnosis, Differential | 6 | 2019 | 1508 | 0.220 |
Why?
| | Decision Support Techniques | 3 | 2019 | 477 | 0.210 |
Why?
| | Heartburn | 2 | 2021 | 12 | 0.210 |
Why?
| | Carcinoma, Pancreatic Ductal | 3 | 2017 | 293 | 0.210 |
Why?
| | Feasibility Studies | 6 | 2024 | 1111 | 0.210 |
Why?
| | DNA, Viral | 1 | 2006 | 356 | 0.210 |
Why?
| | Metabolic Diseases | 1 | 2025 | 114 | 0.210 |
Why?
| | Escherichia coli Infections | 1 | 2005 | 125 | 0.210 |
Why?
| | Program Evaluation | 2 | 2020 | 943 | 0.210 |
Why?
| | Patient Acceptance of Health Care | 2 | 2026 | 881 | 0.200 |
Why?
| | Hypoxia | 1 | 2011 | 1199 | 0.200 |
Why?
| | Case-Control Studies | 7 | 2025 | 3623 | 0.200 |
Why?
| | Sheep | 1 | 2006 | 876 | 0.200 |
Why?
| | Bile Duct Diseases | 2 | 2014 | 13 | 0.200 |
Why?
| | Biomarkers | 6 | 2025 | 4295 | 0.200 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2023 | 28 | 0.200 |
Why?
| | G-Protein-Coupled Receptor Kinase 3 | 1 | 2023 | 2 | 0.200 |
Why?
| | Pancreatitis, Acute Necrotizing | 1 | 2023 | 14 | 0.190 |
Why?
| | Ergonomics | 1 | 2023 | 29 | 0.190 |
Why?
| | Postoperative Hemorrhage | 1 | 2024 | 105 | 0.190 |
Why?
| | Kaplan-Meier Estimate | 3 | 2020 | 969 | 0.190 |
Why?
| | Cytodiagnosis | 2 | 2020 | 31 | 0.190 |
Why?
| | Cholelithiasis | 1 | 2023 | 36 | 0.190 |
Why?
| | Microsurgery | 1 | 2023 | 76 | 0.190 |
Why?
| | Carcinoid Tumor | 1 | 2022 | 21 | 0.190 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2024 | 101 | 0.180 |
Why?
| | Bone Resorption | 1 | 2023 | 81 | 0.180 |
Why?
| | Appendiceal Neoplasms | 1 | 2022 | 28 | 0.180 |
Why?
| | Bone Diseases, Metabolic | 1 | 2023 | 58 | 0.180 |
Why?
| | Forecasting | 1 | 2024 | 390 | 0.180 |
Why?
| | Fluorouracil | 1 | 2023 | 231 | 0.180 |
Why?
| | Surgical Instruments | 3 | 2022 | 51 | 0.180 |
Why?
| | Gastrointestinal Tract | 1 | 2025 | 204 | 0.180 |
Why?
| | Biomedical Research | 2 | 2020 | 717 | 0.180 |
Why?
| | Health Care Surveys | 3 | 2020 | 536 | 0.180 |
Why?
| | Drug Monitoring | 1 | 2026 | 401 | 0.180 |
Why?
| | Hospitalization | 4 | 2026 | 2460 | 0.180 |
Why?
| | Medicare | 2 | 2021 | 903 | 0.180 |
Why?
| | Metabolome | 1 | 2025 | 388 | 0.180 |
Why?
| | Diverticulum, Esophageal | 1 | 2021 | 4 | 0.180 |
Why?
| | Proton Pumps | 1 | 2021 | 8 | 0.170 |
Why?
| | Esophageal Sphincter, Upper | 1 | 2021 | 8 | 0.170 |
Why?
| | Biopsy, Needle | 2 | 2020 | 185 | 0.170 |
Why?
| | Professional Practice Location | 2 | 2019 | 26 | 0.170 |
Why?
| | Dietary Supplements | 1 | 2006 | 583 | 0.170 |
Why?
| | Disease Outbreaks | 1 | 2005 | 419 | 0.170 |
Why?
| | Aspirin | 1 | 2025 | 406 | 0.170 |
Why?
| | Weight Loss | 2 | 2021 | 858 | 0.170 |
Why?
| | Gastrectomy | 2 | 2023 | 166 | 0.170 |
Why?
| | Endoscopes, Gastrointestinal | 1 | 2021 | 13 | 0.170 |
Why?
| | Trefoil Factor-3 | 1 | 2020 | 5 | 0.170 |
Why?
| | Internationality | 2 | 2020 | 156 | 0.170 |
Why?
| | Single-Blind Method | 5 | 2014 | 318 | 0.160 |
Why?
| | Gastric Outlet Obstruction | 1 | 2020 | 12 | 0.160 |
Why?
| | Oral Submucous Fibrosis | 1 | 2020 | 2 | 0.160 |
Why?
| | Radiography, Abdominal | 2 | 2012 | 44 | 0.160 |
Why?
| | Escherichia coli | 1 | 2005 | 835 | 0.160 |
Why?
| | Formative Feedback | 2 | 2024 | 36 | 0.160 |
Why?
| | Digestive System Surgical Procedures | 1 | 2021 | 112 | 0.160 |
Why?
| | Stomach | 2 | 2012 | 111 | 0.160 |
Why?
| | Midazolam | 1 | 2020 | 73 | 0.160 |
Why?
| | Equipment Contamination | 1 | 2021 | 67 | 0.160 |
Why?
| | Varicose Veins | 1 | 2020 | 16 | 0.160 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 412 | 0.160 |
Why?
| | Betacoronavirus | 2 | 2020 | 288 | 0.160 |
Why?
| | Laparotomy | 2 | 2012 | 113 | 0.160 |
Why?
| | United Arab Emirates | 1 | 2020 | 6 | 0.160 |
Why?
| | Esophageal and Gastric Varices | 1 | 2020 | 36 | 0.160 |
Why?
| | Cost-Benefit Analysis | 3 | 2015 | 639 | 0.160 |
Why?
| | Morbidity | 1 | 2021 | 322 | 0.150 |
Why?
| | Emergencies | 1 | 2021 | 174 | 0.150 |
Why?
| | Cecum | 1 | 2019 | 37 | 0.150 |
Why?
| | Colostomy | 1 | 2019 | 28 | 0.150 |
Why?
| | Body Fluids | 1 | 2020 | 71 | 0.150 |
Why?
| | Neostigmine | 1 | 2019 | 21 | 0.150 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2020 | 40 | 0.150 |
Why?
| | Disease Transmission, Infectious | 1 | 2020 | 69 | 0.150 |
Why?
| | Survival Analysis | 2 | 2015 | 1374 | 0.150 |
Why?
| | Dissection | 2 | 2020 | 57 | 0.150 |
Why?
| | Perception | 1 | 2022 | 378 | 0.150 |
Why?
| | Mirizzi Syndrome | 1 | 2019 | 2 | 0.150 |
Why?
| | Accreditation | 1 | 2020 | 101 | 0.150 |
Why?
| | Research Design | 2 | 2020 | 1137 | 0.150 |
Why?
| | Urinary Calculi | 1 | 2019 | 10 | 0.150 |
Why?
| | Disinfection | 1 | 2021 | 131 | 0.150 |
Why?
| | Injections, Intramuscular | 1 | 2019 | 146 | 0.150 |
Why?
| | Saliva | 1 | 2021 | 246 | 0.150 |
Why?
| | Ascites | 1 | 2019 | 48 | 0.150 |
Why?
| | India | 3 | 2018 | 213 | 0.150 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2024 | 1747 | 0.150 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2020 | 325 | 0.150 |
Why?
| | ROC Curve | 4 | 2015 | 617 | 0.140 |
Why?
| | Anastomotic Leak | 1 | 2019 | 45 | 0.140 |
Why?
| | Chronic Disease | 3 | 2019 | 1808 | 0.140 |
Why?
| | Mastitis, Bovine | 1 | 2018 | 2 | 0.140 |
Why?
| | Propensity Score | 2 | 2025 | 377 | 0.140 |
Why?
| | Feedback | 1 | 2019 | 180 | 0.140 |
Why?
| | Obesity, Morbid | 1 | 2023 | 293 | 0.140 |
Why?
| | Esophageal Mucosa | 1 | 2018 | 22 | 0.140 |
Why?
| | Phage Therapy | 1 | 2018 | 17 | 0.140 |
Why?
| | Infection Control | 1 | 2020 | 173 | 0.140 |
Why?
| | Fluoroscopy | 1 | 2019 | 180 | 0.140 |
Why?
| | Plastics | 2 | 2018 | 50 | 0.140 |
Why?
| | Esophagogastric Junction | 3 | 2021 | 55 | 0.140 |
Why?
| | Gallstones | 1 | 2018 | 35 | 0.140 |
Why?
| | Colonoscopes | 3 | 2014 | 5 | 0.130 |
Why?
| | Clinical Protocols | 1 | 2019 | 280 | 0.130 |
Why?
| | Cystadenoma, Serous | 1 | 2018 | 18 | 0.130 |
Why?
| | Quality-Adjusted Life Years | 2 | 2015 | 123 | 0.130 |
Why?
| | Markov Chains | 2 | 2015 | 132 | 0.130 |
Why?
| | Health Status Disparities | 1 | 2021 | 321 | 0.130 |
Why?
| | Diagnostic Techniques and Procedures | 1 | 2017 | 19 | 0.130 |
Why?
| | Reference Standards | 1 | 2018 | 177 | 0.130 |
Why?
| | Aneurysm, False | 1 | 2018 | 46 | 0.130 |
Why?
| | Mortality | 1 | 2020 | 378 | 0.130 |
Why?
| | Cardia | 2 | 2007 | 2 | 0.130 |
Why?
| | Medical Staff Privileges | 1 | 2017 | 4 | 0.130 |
Why?
| | Education | 1 | 2017 | 104 | 0.130 |
Why?
| | Cattle | 3 | 2018 | 946 | 0.130 |
Why?
| | MicroRNAs | 2 | 2015 | 686 | 0.130 |
Why?
| | Optical Imaging | 2 | 2018 | 61 | 0.130 |
Why?
| | Anti-Bacterial Agents | 2 | 2018 | 1923 | 0.130 |
Why?
| | Severity of Illness Index | 6 | 2021 | 2930 | 0.120 |
Why?
| | Credentialing | 1 | 2017 | 21 | 0.120 |
Why?
| | Research | 1 | 2020 | 430 | 0.120 |
Why?
| | Bacteriophages | 1 | 2018 | 110 | 0.120 |
Why?
| | Leiomyoma | 1 | 2017 | 61 | 0.120 |
Why?
| | Iatrogenic Disease | 1 | 2017 | 74 | 0.120 |
Why?
| | Immunoassay | 1 | 2017 | 109 | 0.120 |
Why?
| | Upper Gastrointestinal Tract | 1 | 2016 | 12 | 0.120 |
Why?
| | Quality of Life | 2 | 2024 | 3204 | 0.120 |
Why?
| | Epigenesis, Genetic | 1 | 2021 | 679 | 0.120 |
Why?
| | Patient Discharge | 1 | 2023 | 992 | 0.120 |
Why?
| | Chemoprevention | 2 | 2014 | 92 | 0.120 |
Why?
| | Artificial Intelligence | 1 | 2020 | 381 | 0.110 |
Why?
| | Analysis of Variance | 1 | 2018 | 1300 | 0.110 |
Why?
| | Palliative Care | 2 | 2021 | 1020 | 0.110 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2016 | 76 | 0.110 |
Why?
| | Bariatric Surgery | 1 | 2019 | 252 | 0.110 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2015 | 23 | 0.110 |
Why?
| | Global Health | 1 | 2018 | 403 | 0.110 |
Why?
| | Antibiotic Prophylaxis | 1 | 2016 | 134 | 0.110 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2015 | 58 | 0.110 |
Why?
| | Metals | 3 | 2023 | 136 | 0.110 |
Why?
| | Surveys and Questionnaires | 8 | 2024 | 6066 | 0.110 |
Why?
| | Physicians | 1 | 2024 | 955 | 0.110 |
Why?
| | Costs and Cost Analysis | 1 | 2015 | 221 | 0.110 |
Why?
| | Teaching | 1 | 2017 | 237 | 0.110 |
Why?
| | Intestinal Fistula | 1 | 2014 | 18 | 0.110 |
Why?
| | Guanine Nucleotide Exchange Factors | 1 | 2015 | 63 | 0.110 |
Why?
| | Cryosurgery | 1 | 2015 | 46 | 0.110 |
Why?
| | Administration, Rectal | 2 | 2024 | 14 | 0.110 |
Why?
| | Colorectal Surgery | 1 | 2014 | 30 | 0.100 |
Why?
| | Task Performance and Analysis | 1 | 2015 | 198 | 0.100 |
Why?
| | Body Mass Index | 4 | 2025 | 2445 | 0.100 |
Why?
| | Staphylococcal Infections | 1 | 2018 | 391 | 0.100 |
Why?
| | Combined Modality Therapy | 2 | 2015 | 1266 | 0.100 |
Why?
| | Goblet Cells | 1 | 2013 | 22 | 0.100 |
Why?
| | Prosthesis Failure | 1 | 2014 | 125 | 0.100 |
Why?
| | Health Status | 1 | 2019 | 832 | 0.100 |
Why?
| | Suture Techniques | 1 | 2014 | 137 | 0.100 |
Why?
| | Bone Density | 1 | 2017 | 487 | 0.100 |
Why?
| | Primary Health Care | 2 | 2022 | 1735 | 0.100 |
Why?
| | Patient Participation | 1 | 2017 | 439 | 0.100 |
Why?
| | Animals, Newborn | 2 | 2006 | 891 | 0.100 |
Why?
| | Light | 2 | 2013 | 403 | 0.090 |
Why?
| | Multidetector Computed Tomography | 1 | 2013 | 40 | 0.090 |
Why?
| | Jejunum | 1 | 2012 | 37 | 0.090 |
Why?
| | Polymerase Chain Reaction | 2 | 2006 | 1041 | 0.090 |
Why?
| | Equipment Design | 3 | 2021 | 525 | 0.090 |
Why?
| | Mediastinum | 1 | 2012 | 23 | 0.090 |
Why?
| | Feces | 2 | 2026 | 495 | 0.090 |
Why?
| | Decision Making | 3 | 2023 | 977 | 0.090 |
Why?
| | Young Adult | 8 | 2025 | 14219 | 0.090 |
Why?
| | Peptides | 1 | 2017 | 998 | 0.090 |
Why?
| | Injections, Intravenous | 1 | 2011 | 197 | 0.090 |
Why?
| | Anesthetics, Intravenous | 1 | 2011 | 69 | 0.090 |
Why?
| | Abdomen | 1 | 2012 | 142 | 0.080 |
Why?
| | Guidelines as Topic | 1 | 2012 | 266 | 0.080 |
Why?
| | Carrier Proteins | 1 | 2015 | 728 | 0.080 |
Why?
| | Adrenal Glands | 1 | 2011 | 76 | 0.080 |
Why?
| | Patient Selection | 1 | 2015 | 738 | 0.080 |
Why?
| | Intestines | 1 | 2013 | 354 | 0.080 |
Why?
| | Esophagitis | 2 | 2007 | 67 | 0.080 |
Why?
| | Proteomics | 1 | 2017 | 1188 | 0.080 |
Why?
| | Esophageal pH Monitoring | 1 | 2009 | 22 | 0.080 |
Why?
| | Adolescent | 8 | 2025 | 22530 | 0.070 |
Why?
| | North America | 2 | 2020 | 302 | 0.070 |
Why?
| | Software | 1 | 2014 | 680 | 0.070 |
Why?
| | Veterans | 1 | 2021 | 1635 | 0.070 |
Why?
| | Gastric Acid | 1 | 2009 | 12 | 0.070 |
Why?
| | Antacids | 1 | 2009 | 16 | 0.070 |
Why?
| | Remission Induction | 1 | 2009 | 307 | 0.070 |
Why?
| | National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 2 | 2017 | 10 | 0.070 |
Why?
| | Hematoporphyrin Photoradiation | 1 | 2007 | 1 | 0.070 |
Why?
| | Colonography, Computed Tomographic | 1 | 2007 | 8 | 0.070 |
Why?
| | Gastric Fundus | 1 | 2007 | 2 | 0.070 |
Why?
| | Patient Care Planning | 1 | 2009 | 170 | 0.060 |
Why?
| | Capsule Endoscopy | 1 | 2007 | 25 | 0.060 |
Why?
| | Algorithms | 3 | 2026 | 1845 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2015 | 1061 | 0.060 |
Why?
| | Plasmapheresis | 1 | 2006 | 24 | 0.060 |
Why?
| | Denmark | 1 | 2026 | 51 | 0.060 |
Why?
| | Gastritis | 1 | 2007 | 116 | 0.060 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2026 | 41 | 0.060 |
Why?
| | Overweight | 2 | 2025 | 614 | 0.060 |
Why?
| | CDX2 Transcription Factor | 1 | 2025 | 1 | 0.060 |
Why?
| | Dairying | 1 | 2005 | 12 | 0.060 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2007 | 288 | 0.060 |
Why?
| | Autonomic Nerve Block | 1 | 2024 | 10 | 0.050 |
Why?
| | Celiac Plexus | 1 | 2024 | 7 | 0.050 |
Why?
| | Hyperlipidemias | 1 | 2025 | 120 | 0.050 |
Why?
| | Animals | 6 | 2023 | 38030 | 0.050 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2025 | 79 | 0.050 |
Why?
| | DNA Primers | 1 | 2005 | 505 | 0.050 |
Why?
| | Seasons | 1 | 2006 | 538 | 0.050 |
Why?
| | Virulence | 1 | 2005 | 278 | 0.050 |
Why?
| | Image-Guided Biopsy | 2 | 2015 | 41 | 0.050 |
Why?
| | Glypicans | 1 | 2023 | 11 | 0.050 |
Why?
| | DNA, Bacterial | 1 | 2005 | 320 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 820 | 0.050 |
Why?
| | C-Reactive Protein | 1 | 2026 | 422 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2024 | 172 | 0.050 |
Why?
| | United Kingdom | 1 | 2023 | 344 | 0.050 |
Why?
| | Tumor Burden | 2 | 2015 | 325 | 0.050 |
Why?
| | Anti-Inflammatory Agents | 1 | 2006 | 477 | 0.050 |
Why?
| | Biological Products | 1 | 2026 | 257 | 0.040 |
Why?
| | Pain Measurement | 1 | 2024 | 561 | 0.040 |
Why?
| | Liver | 1 | 2011 | 1896 | 0.040 |
Why?
| | Necrosis | 1 | 2023 | 244 | 0.040 |
Why?
| | Appendectomy | 1 | 2022 | 90 | 0.040 |
Why?
| | Metabolic Syndrome | 1 | 2025 | 360 | 0.040 |
Why?
| | Renal Dialysis | 1 | 2006 | 466 | 0.040 |
Why?
| | Technology | 1 | 2022 | 97 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2024 | 244 | 0.040 |
Why?
| | Colonic Diseases | 2 | 2014 | 37 | 0.040 |
Why?
| | Osteogenesis | 1 | 2023 | 204 | 0.040 |
Why?
| | Blood Transfusion | 1 | 2024 | 409 | 0.040 |
Why?
| | Lifting | 1 | 2020 | 4 | 0.040 |
Why?
| | Induction Chemotherapy | 1 | 2021 | 88 | 0.040 |
Why?
| | Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 5 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2024 | 363 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 171 | 0.040 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 20 | 0.040 |
Why?
| | Cough | 1 | 2021 | 124 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 574 | 0.040 |
Why?
| | Statistics, Nonparametric | 2 | 2012 | 428 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5905 | 0.040 |
Why?
| | Granuloma | 1 | 2020 | 97 | 0.040 |
Why?
| | Personal Protective Equipment | 1 | 2020 | 58 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 2062 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2021 | 136 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2021 | 239 | 0.040 |
Why?
| | Cross-Over Studies | 2 | 2012 | 608 | 0.040 |
Why?
| | Myoviridae | 1 | 2018 | 1 | 0.040 |
Why?
| | Podoviridae | 1 | 2018 | 1 | 0.040 |
Why?
| | Physician-Patient Relations | 1 | 2024 | 588 | 0.040 |
Why?
| | Length of Stay | 1 | 2025 | 1349 | 0.040 |
Why?
| | Pilot Projects | 3 | 2011 | 1891 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2017 | 4148 | 0.040 |
Why?
| | Age of Onset | 1 | 2020 | 555 | 0.030 |
Why?
| | Coloring Agents | 1 | 2018 | 89 | 0.030 |
Why?
| | Rural Population | 1 | 2023 | 659 | 0.030 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2018 | 156 | 0.030 |
Why?
| | Liver Cirrhosis | 1 | 2020 | 287 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2018 | 331 | 0.030 |
Why?
| | Cyst Fluid | 1 | 2018 | 20 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2021 | 465 | 0.030 |
Why?
| | Abdominal Pain | 1 | 2019 | 149 | 0.030 |
Why?
| | Cholecystectomy, Laparoscopic | 1 | 2018 | 55 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2023 | 881 | 0.030 |
Why?
| | Hospitals, University | 1 | 2018 | 176 | 0.030 |
Why?
| | Review Literature as Topic | 1 | 2017 | 52 | 0.030 |
Why?
| | User-Computer Interface | 1 | 2018 | 165 | 0.030 |
Why?
| | Whole Genome Sequencing | 1 | 2018 | 177 | 0.030 |
Why?
| | Granular Cell Tumor | 1 | 2017 | 8 | 0.030 |
Why?
| | Lipoma | 1 | 2017 | 17 | 0.030 |
Why?
| | Communication | 1 | 2024 | 975 | 0.030 |
Why?
| | Mice | 3 | 2023 | 18329 | 0.030 |
Why?
| | Choristoma | 1 | 2017 | 20 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2953 | 0.030 |
Why?
| | Choledochal Cyst | 1 | 2016 | 17 | 0.030 |
Why?
| | Genetic Testing | 1 | 2020 | 480 | 0.030 |
Why?
| | Cancer Pain | 1 | 2017 | 39 | 0.030 |
Why?
| | Diabetes Mellitus | 1 | 2025 | 1097 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2025 | 2803 | 0.030 |
Why?
| | Gastroscopes | 1 | 2016 | 3 | 0.030 |
Why?
| | Genome, Viral | 1 | 2018 | 214 | 0.030 |
Why?
| | Duodenoscopes | 1 | 2016 | 7 | 0.030 |
Why?
| | Biliary Tract Neoplasms | 1 | 2016 | 31 | 0.030 |
Why?
| | Embolism, Air | 1 | 2016 | 14 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 497 | 0.030 |
Why?
| | Exons | 1 | 2017 | 363 | 0.030 |
Why?
| | Cholangitis, Sclerosing | 1 | 2016 | 61 | 0.030 |
Why?
| | Nerve Block | 1 | 2017 | 107 | 0.030 |
Why?
| | DNA Methylation | 1 | 2021 | 674 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2024 | 1149 | 0.030 |
Why?
| | Viral Proteins | 1 | 2018 | 350 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2023 | 2507 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2023 | 3542 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 741 | 0.030 |
Why?
| | Bone and Bones | 1 | 2017 | 317 | 0.030 |
Why?
| | Child, Preschool | 2 | 2022 | 11853 | 0.030 |
Why?
| | Apoptosis | 1 | 2023 | 2440 | 0.030 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2017 | 456 | 0.030 |
Why?
| | Linkage Disequilibrium | 1 | 2015 | 253 | 0.030 |
Why?
| | Child | 3 | 2021 | 22707 | 0.030 |
Why?
| | Equipment Failure | 1 | 2014 | 115 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2022 | 1196 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 407 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2021 | 735 | 0.030 |
Why?
| | Proteome | 1 | 2018 | 514 | 0.020 |
Why?
| | Pathology | 1 | 2013 | 21 | 0.020 |
Why?
| | Health Status Indicators | 1 | 2014 | 167 | 0.020 |
Why?
| | Pain | 1 | 2019 | 789 | 0.020 |
Why?
| | Community Health Centers | 1 | 2013 | 59 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 2017 | 468 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2021 | 2046 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2015 | 335 | 0.020 |
Why?
| | Color | 1 | 2013 | 81 | 0.020 |
Why?
| | Community Health Services | 1 | 2014 | 231 | 0.020 |
Why?
| | Phenotype | 1 | 2021 | 3155 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2013 | 310 | 0.020 |
Why?
| | Adenoma, Villous | 1 | 2012 | 2 | 0.020 |
Why?
| | Databases, Factual | 1 | 2018 | 1490 | 0.020 |
Why?
| | Gastroscopy | 1 | 2011 | 18 | 0.020 |
Why?
| | Sentinel Surveillance | 1 | 2011 | 46 | 0.020 |
Why?
| | Digestive System Neoplasms | 1 | 2011 | 9 | 0.020 |
Why?
| | Base Sequence | 1 | 2015 | 2170 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 330 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2011 | 116 | 0.020 |
Why?
| | Risk | 1 | 2013 | 919 | 0.020 |
Why?
| | Life Style | 1 | 2013 | 485 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2013 | 554 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2017 | 3124 | 0.020 |
Why?
| | Genetic Markers | 1 | 2011 | 335 | 0.020 |
Why?
| | Gene Expression | 1 | 2015 | 1476 | 0.020 |
Why?
| | Mutation | 1 | 2021 | 4075 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 977 | 0.020 |
Why?
| | Linear Models | 1 | 2011 | 845 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2015 | 1407 | 0.020 |
Why?
| | Geography | 1 | 2008 | 187 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2009 | 531 | 0.020 |
Why?
| | Motor Activity | 1 | 2013 | 718 | 0.020 |
Why?
| | Colorado | 1 | 2018 | 4554 | 0.020 |
Why?
| | Diagnostic Equipment | 1 | 2007 | 5 | 0.020 |
Why?
| | Helicobacter Infections | 1 | 2007 | 30 | 0.020 |
Why?
| | Fraud | 1 | 2007 | 11 | 0.020 |
Why?
| | Helicobacter pylori | 1 | 2007 | 44 | 0.020 |
Why?
| | Selenium | 1 | 2007 | 50 | 0.020 |
Why?
| | Electrocoagulation | 1 | 2007 | 35 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2015 | 2158 | 0.020 |
Why?
| | Gastric Mucosa | 1 | 2007 | 54 | 0.020 |
Why?
| | Quality Control | 1 | 2007 | 161 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1716 | 0.020 |
Why?
| | Risk Management | 1 | 2007 | 82 | 0.020 |
Why?
| | Laser Coagulation | 1 | 2007 | 80 | 0.020 |
Why?
| | Leukocyte Count | 1 | 2007 | 316 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 5983 | 0.010 |
Why?
| | Capillaries | 1 | 2007 | 125 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2009 | 779 | 0.010 |
Why?
| | Diagnostic Imaging | 1 | 2007 | 337 | 0.010 |
Why?
| | Monocytes | 1 | 2007 | 539 | 0.010 |
Why?
| | Health Policy | 1 | 2007 | 400 | 0.010 |
Why?
| | Infant | 1 | 2018 | 10077 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2007 | 1323 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2014 | 2214 | 0.010 |
Why?
| | Comorbidity | 1 | 2007 | 1661 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2597 | 0.010 |
Why?
| | Neutrophils | 1 | 2007 | 1124 | 0.010 |
Why?
| | Smoking | 1 | 2007 | 1472 | 0.010 |
Why?
| | Diet | 1 | 2007 | 1277 | 0.010 |
Why?
|
|
Wani's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|